Rigel Pharmaceuticals Reports Record Q3 Net Sales and Provides 2026 Revenue Guidance
Rigel Pharmaceuticals (NASDAQ: RIGL) reported record-breaking third-quarter net product sales of over $72 million, marking its highest quarterly performance to date. The company achieved profitability during the period, driven by strong commercial execution. A key driver for future growth is the recent U.S. launch of VEPPANU, which has already generated $6.6 million in sales since becoming commercially available in August. Looking ahead, management has provided a 2026 revenue outlook ranging between $290 million and $295 million.
Tickers: $RIGL
Topics: earnings report net product sales product launch profitability